Replies to post #144285 on Biotech Values

[DewDiligence]

While I don't think the CRL is the end of the story for Xarelto in ACS…

It may be the end of the story for Xarelto in ACS per se. My guess is that JNJ will decide to refocus on the PCI sub-indication of ACS, which is the subject of a separate NDA submission made in May 2012.